IQVIA (NYSE:IQV) Given New $261.00 Price Target at Stifel Nicolaus

IQVIA (NYSE:IQV) had its target price lowered by Stifel Nicolaus from $273.00 to $261.00 in a research note released on Friday morning,Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

A number of other brokerages also recently weighed in on IQV. Redburn Atlantic assumed coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. The Goldman Sachs Group reduced their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, Bank of America lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $252.39.

IQVIA Stock Performance

Shares of IQV opened at $208.13 on Friday. The company has a market cap of $37.78 billion, a price-to-earnings ratio of 27.75, a P/E/G ratio of 2.25 and a beta of 1.48. The business’s fifty day simple moving average is $200.53 and its two-hundred day simple moving average is $219.80. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts anticipate that IQVIA will post 10.81 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other news, Director John G. Danhakl acquired 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Institutional Trading of IQVIA

Several hedge funds have recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in IQVIA during the third quarter valued at $27,000. Synergy Asset Management LLC purchased a new stake in shares of IQVIA during the 4th quarter valued at about $33,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. Assetmark Inc. grew its position in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares in the last quarter. Finally, UMB Bank n.a. lifted its stake in shares of IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 99 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.